Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

British Journal of Cancer

Topics

Biology

Cancer Oncology

Medicine

Pathology

Internal Medicine

Show all topics

DOI

10.1038/bjc.2017.478

License

CC-BY-NC-SA

Other Formats

PDF